FENNEC PHARMACEUTICALS INC
FENCNASDAQTrading Snapshot
- Day Range
- $12.64 β $13.25
- 52-Week Range
- $5.65 β $13.85
- Volume (shares)
- 398,269
- Avg Volume (shares)
- β
- Shares Outstanding
- 35.3M
- Next Earnings
- 2027-03-22
Fundamentals Snapshot
- Annual Revenue
- $45M
- Last Q Revenue
- $18M
- P/E Ratio
- 571.6
- P/S Ratio
- 7.0x
- EPS (TTM)
- $0.06
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +13.5%
FENNEC PHARMACEUTICALS INC
FENCAbout FENNEC PHARMACEUTICALS INC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

Adherex Technologies (FENC) is on the Move, Here's Why the Trend Could be Sustainable
Adherex Technologies (FENC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-t

What Makes Adherex Technologies (FENC) a New Strong Buy Stock
Adherex Technologies (FENC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

How Much Upside is Left in Adherex Technologies (FENC)? Wall Street Analysts Think 57.8%
The consensus price target hints at a 57.8% upside potential for Adherex Technologies (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisio

Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript

Adherex Technologies Q3 Earnings Call Highlights
Fennec Pharmaceuticals NASDAQ: FENC reported third-quarter net product sales of $19.4 million, up 56% from a year earlier, as use of its hearing-protection drug PEDMARK expanded among new and existing customers.

Adherex Technologies Inc. (FENC) Q3 Earnings and Revenues Beat Estimates
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.02 per share a year ago.